Equity · Healthcare
MPLT
NASDAQMapLight Therapeutics (MPLT)
The line runs 12 USD on 27 August through 9.61 USD on 1 October, on a scale from 8 to 14. Days the market did not trade hold the previous close, flat.
- Market cap
- 407.8M USD
- P/E (TTM)
- 0.2
- EPS, diluted, year to Dec 2025
- −18.56 USD
- Avg volume
- 52.1K
as of Oct 1, 2026
Have MapLight Therapeutics (MPLT) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, MapLight Therapeutics insiders reported 7 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 28 Jul 2026.
Form 4, 90 days to 10 Nov 2026, newest reported trade 15 Oct 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 15 Oct 2026 | Foff Erin PennockChief Medical Officer | Sell | 15,355 | 124K USD |
| 15 Oct 2026 | GILLIS JONATHANCAO and Interim CFO | Sell | 10,167 | 82K USD |
| 15 Oct 2026 | Hanson KristopherGeneral Counsel | Sell | 9,020 | 73K USD |
| 15 Oct 2026 | Kreitzer AnatolChief Discovery Officer | Sell | 12,248 | 96K USD |
| 15 Oct 2026 | Kroeger Christopher A.Chief Executive Officer | Sell | 73,691 | 595K USD |
| 15 Oct 2026 | Lillie James WoodruffChief Scientific Officer | Sell | 11,513 | 93K USD |
| 16 Sep 2026 | Hanson KristopherGeneral Counsel | Sell | 16,509 | 193K USD |
| Sold | 7 open-market sales | 148,503 | $1.26M |
6 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Aug 2026 | Foff Erin PennockChief Medical Officer | Award | 13,360 | |
| 17 Aug 2026 | GILLIS JONATHANCAO and Interim CFO | Award | 8,242 | |
| 17 Aug 2026 | Hanson KristopherGeneral Counsel | Award | 7,730 | |
| 17 Aug 2026 | Kreitzer AnatolChief Discovery Officer | Award | 6,020 | |
| 17 Aug 2026 | Kroeger Christopher A.Chief Executive Officer | Award | 23,145 | |
| 17 Aug 2026 | Lillie James WoodruffChief Scientific Officer | Award | 7,730 |
Which funds hold MapLight Therapeutics (MPLT)?
6 of the 45 institutional funds we track reported a MapLight Therapeutics position for the quarter ended 30 Jun 2026 — a combined 19.4M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Baker Bros. Advisors | Held (±25%) | 364,705 | 13.1M USD | |
| Millennium Management | New position | 128,841 | 4.6M USD | |
| Citadel Advisors | New position | 25,751 | 923K USD | |
| Two Sigma Investments | Trimmed | 8,998 | 322K USD | −36.2% |
| Renaissance Technologies | New position | 6,937 | 249K USD | |
| Marshall Wace | New position | 5,800 | 208K USD | |
| Tudor Investment Corp | Exited |
What has been filed or recorded for MapLight Therapeutics (MPLT)?
The filings we hold for MapLight Therapeutics, newest first: 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 30 Jun 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −1.32 USD | |
| 30 Jun 2026 | Financials | Total assets | 368.3M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 348.3M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −1.34 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −18.56 USD | |
| 31 Dec 2025 | Financials | Net income | −161.2M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −18.56 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −37.18 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2026 reported | EPS −39.11 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2026 reported | EPS −29.33 USD | |
| 31 Dec 2024 | Annual report | FY 2025 reported | EPS −105.38 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2025 reported | EPS −25.08 USD |
What do people ask about MapLight Therapeutics (MPLT)?
What did MapLight Therapeutics shares close at?9.61
MapLight Therapeutics closed at 9.61 USD on 1 Oct 2026, down 3.90% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is MapLight Therapeutics’ market cap?407.8M
MapLight Therapeutics is worth 407.8M USD by market value as of 1 Oct 2026, which is the share price times the shares on issue from its SEC filings.
What is MapLight Therapeutics’ P/E ratio?0.2
MapLight Therapeutics has a price-to-earnings ratio of 0.2, as of 1 Oct 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
Have MapLight Therapeutics insiders bought or sold shares recently?7 sales
In the 90 days to 10 Nov 2026, MapLight Therapeutics insiders reported 7 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 28 Jul 2026. A further 6 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own MapLight Therapeutics?6 of 45
6 of the 45 funds we track reported a MapLight Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, Millennium Management and Citadel Advisors. See Funds
When did MapLight Therapeutics last report earnings?−1.32
MapLight Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −1.32 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings